Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5083945 plus FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone in second-line metastatic colorectal cancer
2010-022983-11Phase 2Terminated
- Sponsor
- Roche
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing RO5083945 + FOLFIRI, cetuximab + FOLFIRI and FOLFIRI alone (3 arms). Primary endpoint: Progression-free survival. Started Nov 2010; status: terminated.
02
Drugs
imgatuzumabcetuximabFOLFIRI
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2010-022983-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022983-11.